Faculty Disclosures

Omni Oncology Tumor Board Chairs

Charu Aggarwal, MD, MPH

Disclosures:

Consultant/Advisor: AstraZeneca, Daiichi Sankyo, Sanofi/Regeneron, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie, Merck Sharp & Dohme, Loxo@Lilly

John Strickler, MD

Disclosures:

Consultant/Advisor: Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Beigene, BMS, Cytovation, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson and Johnson, Jazz Pharmaceuticals, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics

Research Funding: Abbvie, Amgen, Apollo Therapeutics, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/ Genentech

Stock: Triumvira Immunologics (stock options)

Faculty

Tanios S. Bekaii-Saab, MD

Disclosures:

Consultant/Advisor: Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, Takeda, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, Elevar, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline, Xilio, Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma.
Research Funding: Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS.
Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene
WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion
IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, Astra Zeneca, Exelixis, Merck/Eisai, PanCan and 1Globe

Tina Cascone, MD, PhD

Disclosures:

advisor/consultant fees from AstraZeneca, BioNTech, Bristol Myers Squibb, Caris Life Sciences, Daiichi Sankyo, Genentech, Johnson & Johnson, Merck, Moderna, Nuvalent, oNKo Innate/Audax, Pfizer, RAPT Therapeutics, Regeneron, Summit Therapeutics; institutional research grant and/or clinical research support from AstraZeneca, Bristol Myers Squibb and Merck; and honoraria/speaker fees from ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Curio Science, IDEOlogy Health, Medical Educator Consortium, Medscape, OncLive, Physicians’ Education Resources, PeerView, Revolution Medicines, Targeted Oncology.

Martin F. Dietrich, MD, PhD

Disclosures:

Consultant/Advisor: AbbVie, Amgen, Merck

Speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Coherus, Daiichi Sankyo, Eli Lilly & Co., Gilead, Johnson & Johnson, Jazz Pharmaceuticals, EMD Serono, Pfizer, Pharmacosmos, Regeneron, Stemline, Takeda
Research Funding: Bristol Myers Squibb
Speaker: Novartis, Gilead, Fresenius Kabi, Genentech

Samuel J. Klempner, MD

Disclosures:

Consultant/Advisor: Merck, Gilead, BeiGene, I-Mab, Elevation Oncology, AstraZeneca, DaiichiSankyo, Amgen, Eisai,Taiho Oncology, BMS, Gilead, Signet Therapeutics, Boehringer-Ingelheim, EsoBiotec

Jason Mouabbi, MD

Disclosures:

Consultant/Advisor: BostonGene, GE HealthCare, AstraZeneca, Aptitude Health, PreludeDX, Community Health Media​
Research Funding: Bristol Myers Squibb
Speaker: Novartis, Gilead, Fresenius Kabi, Genentech

Shubham Pant, MD, MBBS

Disclosures:

Consulting or Advisory Role: Zymeworks, Ipsen ,Novartis, Janssen, Boehringer Ingelheim, Askgene Pharma, BPGBio, Jazz Pharmaceuticals, Astra Zeneca, US WorldMeds, Nihon Medi-Physics

Research Funding (Clinical Trials. Recipient:  Institution): Mirati Therapeutics , Lilly, Xencor, Novartis, Bristol-Myers Squibb, Ipsen, Astellas Pharma, Purple Biotech, 4D Pharma , Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Biontech, Pfizer, ImmunoMet, Immuneering, Amal Therapeutics.

Zofia Piotrowska, MD, MHS

Consultant/Advisory/Speaker: Boehringer Ingelheim, Janssen, Blueprint Medicines, Lilly, AstraZeneca, Daiichi Sankyo Europe GmbH, AstraZeneca, Taiho Pharmaceutical, Merck, Bayer, Genentech/Roche, Natera, Black Diamond Therapeutics, Cullinan Oncology

Research Funding: Novartis, ARIAD/Takeda, Spectrum Pharmaceutical, AstraZeneca, Cullinan Oncology, Daiichi Sankyo Europe GmbH, AbbVie, Janssen Oncology, Blueprint Medicines, GlaxoSmithKline/Tesaro, Phanes Therapeutics, Roche, Nuvalent Inc, Systimmune

Jacob Sands, MD

Disclosures:

Consultant/Advisor: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Fosun, Genetech, Gilead, Jazz Pharmaceuticals, Lilly, Mariana Oncology, Medtronic, Merck, Novartis, Pharma Mar, Sanofi
Research Funding: Novartis, Harpoon

John P. Sfakianos, MD

Disclosures:

Consultant/Advisor: Natera, Urogen, Pfizer, CG oncology

Nicholas Short, MD

Disclosures:

Consulting fees from Pfizer Inc., GSK, NKARTA, and Sanofi
Research funding from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics, and NextCure
Honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda, Pfizer Inc., Astellas Pharma Inc., Sanofi and BeiGene

Adrienne Waks, MD

Disclosures:

Consultant/Advisor: AMBRX, AstraZeneca
Research Funding: Gilead, Genetech, Macrogenics, Merck
Speaker: AstraZeneca